Publication in "Frontiers in Immunology"

Epalinges, Switzerland, February 22, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Frontiers in Immunology with title: “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques against Mucosal SHIV challenges”

Link to the Publication here